Featured Articles

Developing a Topical Adjunct to Injectable Procedures

By June 24, 2020July 1st, 2020No Comments

Dermatology News

Featured Article

“In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. “

Read Article Now

Developing a Topical Adjunct to Injectable Procedures

New JDD study reveals 81% of subjects applying a topical product had less bruising at day 2/3 compared to the bland moisturizer.

Injectable procedures have come to play an enormous part in everyday  aesthetic medical practice. Whether its use is directed at volumizing with fillers, decreasing volume using enzymes, skin-tightening using multi-needle approaches, or neuromuscular blockade, the injectable route is the means of delivery in all these cases, making injectable procedures the most common aesthetic procedure performed.

As with all procedures, expected and unexpected consequences may follow including bruising, swelling, discomfort, and the possibility of infection. This paper outlines the scientific process and validation of a product designed as an adjunct to injection therapy and the scientific deep dive needed to encompass both symptomatic and adjunctive purposes. On the symptomatic side, bruising, swelling, and pain were considered, while volumetric enhancement, regeneration, and anti-microbial/biofilm effects were desired outcomes from the adjunctive perspective.

Utilizing peptides and active agents aimed at reducing excess residual iron and stimulating macrophage absorption of red blood cells, we were able to achieve efficient resolution of bruising. In addition, peptides were included to stimulate collagen, elastin, and hyaluronic acid in synergy with the injectable. Anti-inflammatory, antimicrobial, and antibiofilm agents were added to aid in the safety profile of the injectable.

In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. Overall, 81% of subjects applying the study topical product had less bruising at day 2/3 compared to the bland moisturizer.

Read Article Now
JDD Article Referenced in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges.

Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges

| Featured Articles, The Latest | No Comments
Featured Article Exosomes are emerging as a cutting-edge innovation in cosmetic dermatology, showing potential in skin rejuvenation, hair restoration, and pigmentation correction. But how close are we to seeing them…
Journal of Drugs in Dermatology JDD Article About Vessel-Targeting Therapies for the Management of Rosacea: A Review of Current Evidence. Image is from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Online Gallery of a woman with a darker skin tone with rosacea.

Vessel-Targeting Therapies for the Management of Rosacea: A Review of Current Evidence

| Featured Articles, The Latest | No Comments
JDD Article Highlight Rosacea’s hallmark redness stems from persistent changes in the skin’s blood vessels. But treatment options targeting these vessels are advancing. Alpha-agonists like oxymetazoline and brimonidine reduce redness, while…
Journal of Drugs in Dermatology JDD Article About Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study. Image from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas. Non-melanoma cancer image of skin of color range from Inclusive Derm Atlas Online Gallery

Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study

| Featured Articles | No Comments
Did You Miss it? Did you miss this compelling article published in the December issue? Non-melanoma skin cancers, like squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), are a…

Leave a Reply